CTIS2022-502419-12-00进行中（未招募）1 期
First-in-Human, Open-label, Dose-Escalation Trial with Expansion Cohorts to Evaluate the Safety of GEN1053 as Monotherapy and in Combination With an Immunomodulator in Subjects with Malignant Solid Tumors - GCT1053-01
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Genmab B.V.
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •For both the Dose Escalation and Expansion parts: Subject must: •Be =18 years of age., •Have measurable disease according to RECIST 1.1, •Provide all pre-baseline scans since failure of last prior therapy (ie documented radiographic PD), if available, •Have Eastern Cooperative Oncology Group performance status =1., •Have organ and bone marrow function as follows: Bone marrow / hematological function: ?Absolute neutrophil count (ANC) =1.5×109/L ?Hemoglobin =9.0 g/dL ?Platelet count =150×109/L Liver function: ?Total bilirubin = upper limit of normal (ULN) ?Alanine aminotransferase =1.5×ULN ?Aspartate aminotransferase =1.5×ULN ?Albumin =30 g/L Coagulation status: ?Prothrombin time (PT)/International normalized ratio =1.5 ?Activated partial thromboplastin time (aPTT) =1.5×ULN Renal function: Glomerular filtration rate =45 mL/min/1.73 m², according to the abbreviated MDRD, For Monotherapy Dose Escalation (phase 1a) and Combination therapy Dose Escalation (phase 1b) only: •Subjects with histologically or cytologically confirmed non-CNS solid tumors that are metastatic or advanced., •Subjects who have progressed on standard of care therapy or for whom there is no available standard therapy likely to provide clinical benefit, or who are not candidates for available therapy or who have previously refused available therapy, and for whom, experimental therapy with GEN1053 or GEN1053+IM may be beneficial, in the opinion of the investigator., •Fresh biopsies mandatory for all patients in Monotherapy Dose Escalation and Combination therapy Dose Escalation, For the Expansion part Only: •Subjects with histologically or cytologically confirmed diagnosis of recurrent, unresectable or metastatic HNSCC or metastatic NSCLC, who do not have any further available standard therapy or who are not candidates for standard therapy or who have previously refused standard therapy (if subjects had access), and for whom experimental therapy with GEN1053 or GEN1053+IM may be beneficial, in the opinion of the investigator.
排除标准
- •Has uncontrolled intercurrent illness, including but not limited to: -Ongoing or active infection requiring IV treatment with anti-infective therapy administered less than 2 weeks prior to first dose. -Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris or cardiac arrhythmia. -Uncontrolled hypertension defined as systolic blood pressure =160 mm Hg and/or diastolic blood pressure =100 mm Hg, despite optimal medical management. -Prolonged QTc interval at baseline of =470 milliseconds using Fridericia's QT correction formula. -Ongoing or recent (within 1 year) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs. -History of grade 3 or higher irAEs that led to treatment discontinuation of a CPI. -History of chronic liver disease or evidence of hepatic cirrhosis. -Evidence of interstitial lung disease. -Ongoing pneumonitis or history of non-infectious pneumonitis that has required steroids. -Known platelet function defects., •Prior therapy: -Radiotherapy within 14 days prior to first GEN1053 administration. Palliative radiotherapy will be allowed. -Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to GEN1053 administration. -Subject with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment. Inhaled or topical steroids, and adrenal or pituitary replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
研究者
相似试验
进行中（未招募）
1 期
GEN1046 Safety Trial in Patients With Malignant Solid TumorsMalignant solid tumors:Patients with relapsed or refractory, advanced and/or metastatic non-small cell lung cancer (NSCLC), endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer who are no longer candidates for or refuse (if subjects had access and were eligible for the respective treatments) standard therapy.MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003402-63-HUGenmab A/S652
招募中
1 期
Trial to assess the safety and preliminary efficacy of GEN1055 on malignant solid tumors as monotherapy and as combination therapy.Malignant Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2023-507049-28-00Genmab A/S225
进行中（未招募）
1 期
A Safety study of GEN1047 in patients with malignant solid tumorsMalignant Solid Tumors, per protocol GCT1047-01MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2021-001790-23-ESGenmab A/S380
进行中（未招募）
1 期
A Safety study of GEN1044 in patients with malignant solid tumors.EUCTR2019-003998-26-ESGenmab A/S378
招募中
1 期
GEN1047 for Solid Tumors - First in Human (FIH) TrialMalignant Solid TumorsMedDRA version: 21.1Level: LLTClassification code: 10065147Term: Malignant solid tumor Class: 10029104CTIS2024-510722-10-00Genmab A/S333